Frankfurt - Delayed Quote EUR
Moberg Pharma AB (publ) (MB8.F)
As of 8:17 AM GMT+1. Market Open.
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Anna Ljung BA, M.Sc. | Chief Executive Officer | 2.93M | -- | 1980 |
| Ms. Marie Moberg | Co-Founder | 193.7k | -- | -- |
| Mr. Mark Beveridge | Vice President of Finance | -- | -- | 1978 |
| Dr. Christina Erixon | Head of Pharmaceutical Development & Operations | -- | -- | 1970 |
| Dr. Amir Tavakkol Ph.D. | Chief Scientific Officer | -- | -- | 1955 |
| Gunilla Wengstr?m | Senior Director of Sales & Marketing | -- | -- | -- |
| Anders Broijersen M.D., Ph.D. | Chief Medical Officer | -- | -- | 1964 |
| Mr. Robert Ehrl | Head of Supply | -- | -- | 1967 |
Moberg Pharma AB (publ)
- Sector:?
- Healthcare
- Industry:? Drug Manufacturers - Specialty & Generic
- Full Time Employees:?
- 9
Description
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.
Corporate Governance
Moberg Pharma AB (publ)’s ISS Governance QualityScore as of November 1, 2024 is 8. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 4; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
November 12, 2024 at 10:59 AM UTC
Moberg Pharma AB (publ) Earnings Date
Recent Events
November 4, 2019 at 12:00 AM UTC
Ex-Dividend Date